Price and scope of application of Lurbinectedin

Lurbinectedin (Lurbinectedin) has not yet been launched in China, so it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase Rubinectedin through overseas channels. There is only the original drug Rubicatin in foreign countries, and the price is relatively expensive. In comparison, the original drug in Singapore is slightly cheaper, priced at more than 30,000, and there are other American versions of the original drug, priced at more than 90,000.

Rubicardin’s scope of application mainly includes the following two specific types of cancer:

1.Recurrent small cell lung cancer (SCLC): Rubicatin is approved to treat recurrent small cell lung cancer, a subtype of lung cancer. Small cell lung cancer is usually a more malignant cancer that is characterized by rapid growth and spread. Recurrent means the cancer has reappeared or progressed after treatment, in which case rubicartin may be an option.

2.Recurrent synovial sarcoma (Myxoid/round cell liposarcoma): Rubicatin is also approved to treat recurrent synovial sarcoma, a soft tissue tumor. Synovial sarcoma usually originates in fatty tissue, and recurrent means the tumor reappears or progresses after treatment. Rubicatin may be used as a treatment option in this condition.

It is important to note that rubicatin may not have an approved indication in the treatment of other types of cancer. It is a targeted drug with a specific mechanism of action and is mainly used for the two specific types of cancer mentioned above. Treatment plans are usually formulated by doctors based on the patient's specific situation and cancer type, including determination of dosage and treatment cycles.

Patients should discuss treatment options, expected effects, and possible risks and side effects with their doctor in depth before receiving rubicatin. Treatment plans should be developed by medical professionals based on the patient's specific circumstances to ensure optimal treatment results. Because rubicatin is an injectable form, treatment needs to be administered in a medical facility or hospital and administered and monitored by experienced medical staff.